Xanthan Gum (E415) and Gut Inflammation
New scientific evidence and what it means for manufacturers

Xanthan gum (E415) is one of the most widely used food additives globally. Produced biotechnologically through fermentation by the bacterium Xanthomonas campestris, it gives products their desired texture — from creamy ice cream through stable sauces to gluten-free pasta. For decades it was considered biologically inert: indigestible, safe, without effect on the body. New research from the Federal University of São Paulo (UNIFESP) changes this picture, providing the first experimental evidence that chronic xanthan gum consumption causes colon inflammation and damages the intestinal barrier.

Background: what is xanthan gum and where will you find it

E415 is an exopolysaccharide — a complex sugar produced by Xanthomonas campestris, the same plant pathogen that in nature infects brassicas like cabbage and kale, causing them to spoil. In the industrial process, the bacterium ferments a substrate (typically glucose or sucrose), producing a viscous substance with exceptional rheological properties.

Xanthan gum serves the food industry as:

• Thickener — provides consistency to sauces, dressings, instant soups
• Emulsion stabiliser — prevents separation in ice cream, beverages, yoghurt
• Gelling agent — replaces gluten in gluten-free baked goods
• Medical fluid thickener — aids swallowing for people with dysphagia

It is also an ingredient in many protein shakes, liquid-form dietary supplements, and ultra-processed foods. The global xanthan gum market is estimated to exceed USD 1 billion annually.

The UNIFESP study: what was actually demonstrated

The study published in April 2026 in PLOS ONE (Rischiteli et al., DOI: 10.1371/journal.pone.0347232) was a 10-week experiment on rats receiving xanthan gum at varying doses. Key findings:

• Colon inflammation — histopathological examination revealed higher inflammation scores in animals receiving E415, with increased numbers of lymphocytes within the intestinal wall.
• Claudin-2 upregulation — the protein that regulates permeability in tight junctions between intestinal epithelial cells was overexpressed, indicating opening of the intestinal barrier.
• Elevated pro-inflammatory cytokines — IL-1β and TNF-α were significantly higher in rats fed xanthan gum. TNF-α is particularly associated with epithelial cell death and the development of inflammatory bowel diseases.
• Microbiota dysbiosis — although overall alpha diversity did not decrease significantly, there was a shift in microbial group proportions, including an increase in Elusimicrobiota — a phylum associated with inflammatory conditions.

The strongest effects were observed at medium and high doses. The authors emphasise this is not about demonising the substance, but about signalling the need for translational studies in humans.

Mechanism: how xanthan gum damages the intestinal barrier

The intestinal barrier is a single layer of epithelial cells (enterocytes) connected by tight junction proteins. The claudin family plays a critical role. Claudin-2 forms permeability channels — its overexpression means the barrier becomes "leaky" (a phenomenon often referred to as leaky gut).

According to the study authors, the mechanism unfolds as follows:

1. Xanthan gum reacts with the intestinal epithelium
2. Claudin-2 is upregulated in tight junctions
3. The intestinal barrier loses integrity — permeability increases
4. Antigens and bacterial fragments penetrate into submucosal tissue
5. Lymphocyte recruitment and activation of inflammatory response
6. Increased production of pro-inflammatory cytokines (IL-1β, TNF-α)
7. TNF-α induces enterocyte apoptosis — further barrier damage

This self-reinforcing cycle explains why effects accumulate over time and at higher doses.

flowchart TD
    A[Chronic xanthan gum\nconsumption E415] --> B[Interaction with\ncolon epithelium]
    B --> C[Claudin-2 upregulation\nin tight junctions]
    C --> D[Loss of intestinal\nbarrier integrity]
    D --> E[Antigen and bacterial\nfragment translocation]
    E --> F[Lymphocyte recruitment\ninto intestinal wall]
    F --> G[IL-1beta and TNF-alpha\nelevation]
    G --> H[TNF-alpha induces\nenterocyte apoptosis]
    H --> D
    G --> I[Moderate-grade\ncolon inflammation]
    style A fill:#1e3a5f,stroke:#38bdf8,color:#e2e8f0
    style D fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style I fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style H fill:#92400e,stroke:#f59e0b,color:#fef3c7

Historical context: premature infants, SimplyThick, and NEC

The new study did not emerge in a vacuum. As early as 2012, Beal et al. described in The Journal of Pediatrics a series of 22 cases of necrotizing enterocolitis (NEC) in premature infants in the US. The common factor was formula thickened with SimplyThick, a product whose primary thickening component is xanthan gum.

At least 3 neonates died. NEC is a severe condition involving intestinal tissue death — potentially fatal in immunologically immature preterm infants. The FDA issued a warning and prohibited the use of xanthan gum-based thickeners in premature infants.

Until now, the link between E415 and NEC was merely a clinical hypothesis — an empirical observation without an explained mechanism. The Brazilian study provides the missing link: intestinal barrier opening via Claudin-2 → inflammatory cascade → tissue damage. In the immature gut of a premature infant, this mechanism could lead to full-blown NEC.

Xanthan gum and microbiota: not as inert as once believed

For years the dogma held: xanthan gum is not digested by the human body, passes through the gastrointestinal tract unchanged. Research by Ostrowski et al. published in 2022 in Nature Microbiology overturned this concept.

It turns out that gut bacteria — specifically a species from the Ruminococcaceae family — have evolved the ability to degrade xanthan gum. The breakdown products (oligosaccharides) are then fermented by Bacteroides intestinalis into short-chain fatty acids (SCFAs). In other words: xanthan gum is not biologically inert — it influences the composition and metabolism of the gut microbiome.

The 2026 Brazilian study adds to this picture: chronic E415 administration increased the proportion of bacteria from the phylum Elusimicrobiota, associated with inflammatory states. This increase occurred without dramatic change in overall alpha diversity — indicating subtle but potentially clinically significant dysbiosis.

Together, these two discoveries form a coherent picture: xanthan gum is metabolised by the microbiota, alters its composition, and the products of this metabolism or the direct interaction with the epithelium may trigger an inflammatory response.

flowchart LR
    subgraph OLD["FORMER PARADIGM"]
        direction TB
        D1[Xanthan gum E415]
        D2[Not digested]
        D3[Passes through gut\nunchanged]
        D4[Biologically inert]
        D1 --> D2 --> D3 --> D4
    end
    subgraph NEW["CURRENT KNOWLEDGE 2022-2026"]
        direction TB
        N1[Xanthan gum E415]
        N2[Degraded by\nRuminococcaceae]
        N3[Oligosaccharides fermented\nby B. intestinalis to SCFAs]
        N4[Microbiota composition shift\nElusimicrobiota increase]
        N5[Epithelial interaction\nClaudin-2 upregulation]
        N6[Colon inflammation]
        N1 --> N2 --> N3
        N1 --> N4
        N1 --> N5 --> N6
    end
    OLD -.->|Overturned by\n2022-2026 research| NEW
    style D4 fill:#064e3b,stroke:#10b981,color:#d1fae5
    style N6 fill:#7f1d1d,stroke:#f87171,color:#fecaca

Regulatory status of E415 in the EU: what the law says today

Xanthan gum is an authorised food additive in the EU under Regulation (EC) No 1333/2008. Key regulatory facts:

• EFSA 2017 (EFSA Journal 2017;15(7):4909) — re-evaluation of E415. The ANS panel did not establish an ADI (acceptable daily intake), finding the substance safe at current use levels. No genotoxicity or carcinogenicity was identified.
• EFSA 2023 (EFSA Journal 2023;21(5):7951) — additional safety assessment of E415 in food for infants below 16 weeks of age. The FAF panel raised no safety concerns for use in food category 13.1.
• No established ADI — paradoxically, not because it is dangerous, but because at the time of assessment no adverse effects were observed even at the highest tested doses.
• Permitted level — quantum satis for most food categories (no quantitative restrictions beyond GMP).

Critical point: the EFSA 2017 re-evaluation did not consider the UNIFESP study (published only in 2026) nor the Nature Microbiology discovery (2022) about E415 metabolism by gut microbiota. The scientific basis underlying the safety assessment is therefore incomplete in light of the latest data.

Consequences for food and supplement manufacturers

While a single rat study does not change the law, it changes the risk landscape. Here are the practical implications:

1. Ultra-processed food manufacturers

E415 is present in many products simultaneously (sauce + ice cream + yoghurt + supplement). Cumulative daily intake for a typical consumer of highly processed food may exceed doses tested in safety studies. It is worth conducting an internal audit of E415 content across the product portfolio and considering reduction where alternatives (e.g., modified starch, guar gum) are technically feasible.

2. Dietary supplement manufacturers

E415 is sometimes used as an excipient in liquid and gel supplement forms. For supplements intended for daily, long-term use (probiotics, vitamins, omega-3), a reformulation should be considered — particularly as the described mechanism (intestinal barrier loosening) directly contradicts the declared purpose of probiotics.

3. Infant food and dysphagia product manufacturers

These are the most vulnerable populations. Infants have an immature intestinal barrier; people with dysphagia consume thickeners daily. The study authors' recommendation: monitor gut health of patients using thickeners and consider protective strategies (e.g., probiotics).

4. R&D and quality departments

Documentation justifying the use of E415 should account for the latest scientific data as part of risk assessment (due diligence). In the event of inspections or a potential EFSA re-evaluation, a manufacturer with a current risk analysis is in a stronger position than one relying solely on the 2017 opinion.

flowchart TD
    A[New scientific data\non E415 - UNIFESP 2026] --> B{Manufacturer type?}
    B -->|Ultra-processed food| C[Audit cumulative E415\nacross product portfolio]
    B -->|Dietary supplements| D[Assess: is E415\nessential in formulation?]
    B -->|Infant food and\ndysphagia products| E[Highest priority:\nconsider alternatives]
    C --> F[Reduce where\nalternatives feasible]
    D --> G[Especially probiotics:\nmechanistic contradiction]
    E --> H[Monitor gut health\n+ protective strategies]
    F --> I[Update risk assessment\ndocumentation due diligence]
    G --> I
    H --> I
    I --> J[Readiness for potential\nEFSA re-evaluation]
    style E fill:#7f1d1d,stroke:#f87171,color:#fecaca
    style J fill:#1e3a5f,stroke:#38bdf8,color:#e2e8f0

What the study does NOT prove — and why that matters

A rigorous analysis requires acknowledging limitations:

• Animal model ≠ humans. The rat gut differs from the human gut in length, microbiota composition, and metabolism. Extrapolation requires caution.
• Doses may not reflect real human intake. The study used controlled doses; human consumption is more variable and typically lower.
• No data on occasional consumption. The authors themselves emphasise that sporadic intake in small quantities as an additive probably causes no harm. The concern is about daily exposure.
• One study is not a consensus. Replication, studies on other models, and — above all — human studies are needed.

However: this study is not isolated. It fits into a broader picture formed by the discovery of E415 metabolism by gut microbiota (2022), earlier NEC cases (2012), and research showing that xanthan gum does not improve colitis outcomes and promotes Ruminococcus gnavus growth (Wang et al., 2023). The scientific signal is accumulating.

What next? Regulatory scenarios

Based on analysis of EFSA procedures and precedents (e.g., titanium dioxide E171, carrageenan E407), likely scenarios can be outlined:

1. Scenario 1 (most likely short-term): No immediate regulatory changes. A single rat study is insufficient to trigger the Article 32 procedure. EFSA awaits replication and human data.
2. Scenario 2 (medium-term, 2-4 years): The Commission requests EFSA to reassess E415 incorporating new data. Possible establishment of an ADI or restrictions for specific populations (infants, people with IBD).
3. Scenario 3 (unlikely): Withdrawal of authorisation. This would require multiple, consistent evidence in humans — the E171 analogy took over a decade.

Conclusions

Xanthan gum is not a poison. It is a legal, widely used food additive with proven technological properties. But new scientific data from 2022 and 2026 fundamentally change our understanding of its interaction with the body:

• It is not biologically inert — it is metabolised by the gut microbiota
• Under chronic consumption it can open the intestinal barrier via Claudin-2 upregulation
• It triggers an inflammatory cascade involving TNF-α and IL-1β (at least in rats)
• Historical NEC cases in premature infants gain a mechanistic explanation

For food manufacturers, this is not cause for panic but cause for proactive action: updating risk assessments, considering alternatives for products targeting vulnerable populations, and preparing for potential regulatory re-evaluation. The manufacturer who acts pre-emptively will be better prepared than one caught off guard by regulatory change.

Disclaimer: Tomasz Krawczyk — author specialising in EU and Polish food law and dietary supplements. supplemental.pl · foodlaw.ai. This material is for general information purposes and reflects the state of affairs as of July 2026; it does not constitute legal advice in any individual case.